IN THE UNITED STATES PATENT & TRADEMARK OFFICE

the Application of: Cantrell et al. Application No.: 10/530,446

Filed: April 5, 2005

Atty. File No.: 1585 WO/US

Title: Process For The Preparation of

Quaternary N-alkyl Morphinan

Alkaloid Salts

Group Art Unit: 1625

Examiner: Not yet assigned

CERTIFICATE OF TRANSMISSION

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING MAILED USING THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL TO THE U.S. PATENT & TRADEMARK OFFICE ON JUNE 28, 2006.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with duties imposed by 37 CFR §1.56 and means for complying therewith according to 37 CFR §§1.97-1.98, the references listed on the attached Form PTO/SB/08A are called to the attention of the US Patent & Trademark Office in relation to the present application.

No representation is made that the cited references are the only art or that the citied references represents the best art. The Examiner is urged to consider all of the cited references and to make an independent evaluation of the teachings and materiality of each.

Since this correspondence is being submitted prior to a first Office Action on the merits, it is believed that no fee is due. However, if a fee is required for entry of this correspondence, please charge Deposit Account No. 13-1160.

Respectfully submitted,

Christine M. Rebman (Reg. No. 50,546)

Comoner. Deb

christine.rebman@tycohealthcare.com

314-654-3939

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

2

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known 10/530,446 **Application Number** Filing Date April 5, 2005 Gary L. CANTRELL First Named Inventor Art Unit 1625 **Examiner Name** Not yet assigned 1585 WO/US **Attorney Docket Number**

(use as many sheets as necessary) Sheet 1 of

U.S. PATENT DOCUMENTS Name of Patentee or Pages, Columns, Lines, Where **Document Number Publication Date** Examiner Cite MM-DD-YYYY Applicant of Cited Relevant Passages or Relevant Figures Initials* No.1 Number-Kind Code² Document Appear (if known) 25 US 3101339 08-20-1963 Zeile et al.

FOREIGN PATENT DOCUMENTS						
	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°
		Country Code ³⁻ Number ⁴⁻ Kind Code ⁵ (if known)				
	26	PL 124 001	07-01-1985	Gorecki et al.		

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1Applicant's unique citation designation number (optional). 2See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. sKind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

			Complete if Known		
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/530,446
				Filing Date	April 5, 2005
				First Named Inventor	Gary L. CANTRELL
(use as many sheets as necessary)		Art Unit	1625		
		Examiner Name	Not yet assigned		
Sheet	2	of	2	Attorney Docket Number	1585 WO/US

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	T²
Initials*	No.1	The item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	27	MUSICH et al., Reaction of O-methyl-N, N¹-Diisopropylisourea with Amino Acids and Amines, Journal of Organic Chemistry (1977), 42(1), pp. 139-141	
	28	GIGER et al., Synthesis and Reactions of the diels-Alder Adduct of Thebaine with 4-phenyl-1,2,4-triazoline-3,5-dione, Tetrahedron (1973), 29(16), pp. 2387-2391	
	29	KOCZKA et al., Selective Quaternization of Compounds with Morphine Skeleton, Acta. Chim. Acad. Sci. Hung. (1967), 51(4), pp. 393-402	
	30	SEKI, Isao, Studies on the Morphine Alkaloids and its Related Compounds. XIV. Preparation of 6-Amino-hydrophenanthrene Compounds from Hofmann Degradation Products of the Morphine Alkaloids, Chemical & Pharmaceutical Bulletin (1966), 14(5), pp. 453-461	-
	31	FRY et al., Mannich Derivatives of Analgesic Agents, Journal of Organic Chemistry (1959), 24, pp. 116-117	
	32	BENTLEY et al., The Reduction of Thebaine and Dihydrothebaine by Sodium and Ammonia, Journal of the Chemical Society, Abstracts (1952), pp. 958-966	
	33	SCHULTZ et al., Thebaine Cyclopropanation, Russian Journal of Organic chemistry (Translation of Zhurnal Organicheskoi Khimii) (2003), 39(8), pp. 1083-1088	
	34	OTTO et al., Selection and Amplification of Hosts from Dynamic combinatorial Libraries of Macrocyclic Disulfides, Science (Washington, DC, United States) (2002), 297(5581), pp. 590-593 & Supporting Online Material	-
	35	LOPEZ et al., Photoxidation of Thebaine. A Route to 14-Hydroxymorphinones and Hydrodibenzofuran Analogs of Methadone, Tetrahedron Letters (1994), 35(31), pp. 5727-5730	
	36	MANOHARAN et al., Stereoselectivity in Quaternization of Thebaine: 270 MHz PMR Spectroscopic Studies, Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal chemistry (1987), 26B(2), pp. 140-142	
	37	SHULTS et al., Tranformations of Quaternary Tetrahydrothebaine Sulfones, Zh. Org. Khim. (1993), 29(6), pp. 1149-1162. (English pages 953-963)	
	38	FUNKE et al., A ¹ H and ¹³ C Nuclear Magnetic Resonance Study of Three Quaternary Salts of Naloxone and Oxymorphone, J. Chem. Soc. Perkin Trans. (1986) 2, pp. 735-738	
	39	LOPEZ et al., The [4+2] Addition of Singlet Oxygen to Thebaine: New Access to Highly Functionalized Morphine Derivatives via Opioid Endoperoxides, J. Org. Chem. (2000), 65(15), pp. 4671-4678	·

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.